Sign in
AKTS Stock Price, Chart, Stats & News
Aktis Oncology, Inc.
Save
Aktis Oncology, Inc. (AKTS) does not currently pay a dividend.
1.04B
Market cap
–
Current P/E
–
Forward P/E
AKTS chart
Fundamentals
Gross margin | 100.00% |
Operating margin | -3500.34% |
Pretax margin | -2957.63% |
Net margin | -2957.63% |
Effective tax rate | – |
ROA | -13.48% |
ROE | 65.59% |
D/E | -0.14x |
Interest coverage ratio | – |
AKTS valuation
P/E | – |
P/S | 544.44x |
P/B | – |
P/CF | – |
P/FCF | 68.03x |
P/OCF | – |
PEG | – |
EV multiple | -16.54x |
About
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer.
Similar securities
Based on sector and market capitalization
Report issue